A Randomised, Double-blind, Placebo-controlled Trial to Assess the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults
Latest Information Update: 06 Mar 2025
At a glance
- Drugs EP 395 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors EpiEndo Pharmaceuticals
Most Recent Events
- 27 Feb 2025 Status changed from not yet recruiting to recruiting.
- 13 Nov 2024 New trial record